Literature DB >> 10364099

Antithrombotic therapy in cancer.

A K Kakkar, R C Williamson.   

Abstract

Entities:  

Mesh：

Substances：

Year:  1999        PMID： 10364099      PMCID： PMC1115952          DOI： 10.1136/bmj.318.7198.1571

Source DB:  PubMed          Journal:  BMJ        ISSN： 0959-8138


× No keyword cloud information.
  11 in total

1.  Lower mortality in cancer patients treated with low-molecular-weight versus standard heparin.

Authors:  D Green; R D Hull; R Brant; G F Pineo
Journal:  Lancet       Date:  1992-06-13       Impact factor: 79.321

Review 2.  Antithrombotic therapy for venous thromboembolic disease.

Authors:  T M Hyers; G Agnelli; R D Hull; J G Weg; T A Morris; M Samama; V Tapson
Journal:  Chest       Date:  1998-11       Impact factor: 9.410

3.  The risk of a diagnosis of cancer after primary deep venous thrombosis or pulmonary embolism.

Authors:  H T Sørensen; L Mellemkjaer; F H Steffensen; J H Olsen; G L Nielsen
Journal:  N Engl J Med       Date:  1998-04-23       Impact factor: 91.245

Review 4.  Prevention of post-operative deep leg vein thrombosis in patients with cancer.

Authors:  A S Gallus
Journal:  Thromb Haemost       Date:  1997-07       Impact factor: 5.249

5.  Increased thromboembolic complications with concurrent tamoxifen and chemotherapy in a randomized trial of adjuvant therapy for women with breast cancer. National Cancer Institute of Canada Clinical Trials Group Breast Cancer Site Group.

Authors:  K I Pritchard; A H Paterson; N A Paul; B Zee; S Fine; J Pater
Journal:  J Clin Oncol       Date:  1996-10       Impact factor: 44.544

Review 6.  Prevention of thrombotic disorders in cancer patients undergoing chemotherapy.

Authors:  M N Levine
Journal:  Thromb Haemost       Date:  1997-07       Impact factor: 5.249

Review 7.  Tissue factor in cancer angiogenesis and metastasis.

Authors:  W Ruf; B M Mueller
Journal:  Curr Opin Hematol       Date:  1996-09       Impact factor: 3.284

8.  Involvement of platelets in tumour angiogenesis?

Authors:  H M Pinedo; H M Verheul; R J D'Amato; J Folkman
Journal:  Lancet       Date:  1998-11-28       Impact factor: 79.321

9.  Fatal pulmonary embolism in cancer patients: is heparin prophylaxis justified?

Authors:  V S Shen; E W Pollak
Journal:  South Med J       Date:  1980-07       Impact factor: 0.954

10.  Venous thromboembolism and cancer.

Authors:  J A Baron; G Gridley; E Weiderpass; O Nyrén; M Linet
Journal:  Lancet       Date:  1998-04-11       Impact factor: 79.321
View more
  8 in total

1.  Low molecular weight heparins could be important in cancer.

Authors:  S Siragusa
Journal:  BMJ       Date:  1999-09-25

Review 2.  The hypercoagulable state of malignancy: pathogenesis and current debate.

Authors:  Graham J Caine; Paul S Stonelake; Gregory Y H Lip; Sean T Kehoe
Journal:  Neoplasia       Date:  2002 Nov-Dec       Impact factor: 5.715

Review 3.  Molecular pathology of tumor metastasis III. Target array and combinatorial therapies.

Authors:  József Tímár; Andrea Ladányi; István Peták; András Jeney; László Kopper
Journal:  Pathol Oncol Res       Date:  2003-04-18       Impact factor: 3.201

4.  Ovarian cancer, the coagulation pathway, and inflammation.

Authors:  Xipeng Wang; Ena Wang; John J Kavanagh; Ralph S Freedman
Journal:  J Transl Med       Date:  2005-06-21       Impact factor: 5.531

5.  Platelet microparticle-mediated transfer of miR-939 to epithelial ovarian cancer cells promotes epithelial to mesenchymal transition.

Authors:  Meiling Tang; Lu Jiang; Yingying Lin; Xiaoli Wu; Kai Wang; Qizhi He; Xipeng Wang; Weiping Li
Journal:  Oncotarget       Date:  2017-10-27

6.  FRAGMATIC: a randomised phase III clinical trial investigating the effect of fragmin added to standard therapy in patients with lung cancer.

Authors:  Gareth O Griffiths; Sarah Burns; Simon I Noble; Fergus R Macbeth; David Cohen; Timothy S Maughan
Journal:  BMC Cancer       Date:  2009-10-06       Impact factor: 4.430

Review 7.  The potential benefits of low-molecular-weight heparins in cancer patients.

Authors:  Francisco Robert
Journal:  J Hematol Oncol       Date:  2010-01-14       Impact factor: 17.388

8.  Safety, Pharmacokinetics, Pharmacodynamics, and Antitumor Activity of Necuparanib Combined with Nab-Paclitaxel and Gemcitabine in Patients with Metastatic Pancreatic Cancer: Phase I Results.

Authors:  Eileen M O'Reilly; James Roach; Paul Miller; Kenneth H Yu; Catherine Tjan; Molly Rosano; Silva Krause; William Avery; Julie Wolf; Keith Flaherty; Darrell Nix; David P Ryan
Journal:  Oncologist       Date:  2017-11-20
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.